Clover Health Q2 revenue beats expectations
Overview
Clover Health Q2 2025 rev grows 34% yr/yr, beating analyst expectations, per LSEG data
Adjusted EBITDA for Q2 beats consensus, reaching $17 mln
Company reports GAAP net loss of $11 mln for Q2
Outlook
Clover Health maintains full-year insurance revenue guidance at $1.800 bln - $1.875 bln
Company improves full-year Adjusted SG&A to $335 mln - $345 mln
Clover Health expects Insurance BER between 88.5% - 89.5%
Company anticipates average Medicare Advantage membership of 104,000 - 108,000
Result Drivers
TECHNOLOGY-FIRST MODEL - Co attributes growth to technology-first model, focusing on affordability and AI-driven clinical recommendations, per CEO Andrew Toy
MEMBERSHIP GROWTH - Medicare Advantage membership increased by 32% yr/yr, reaching 106,323 members
CLOVER ASSISTANT IMPACT - Co reports improved health outcomes with Clover Assistant technology, citing fewer hospitalizations and readmissions for COPD
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $478 mln | $468.30 mln (4 Analysts) |
Q2 Net Income | -$11 mln | ||
Q2 Adjusted EBITDA | Beat | $17 mln | $16.30 mln (4 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the managed healthcare peer group is "buy."
Wall Street's median 12-month price target for Clover Health Investments Corp is $4.50, about 36% above its August 4 closing price of $2.88
Press Release:
